作者
Friederike Holze, Anna M Becker, Karolina E Kolaczynska, Urs Duthaler, Matthias E Liechti
发表日期
2023/4
期刊
Clinical Pharmacology & Therapeutics
卷号
113
期号
4
页码范围
822-831
简介
- Psilocybin is being investigated as a potential treatment for psychiatric and neurological disorders. Only a few studies have evaluated the pharmacokinetics (PKs) of psilocybin and have used body weight‐adjusted dosing. Data on PKs and the PK‐pharmacodynamic (PD) relationship of fixed doses that are commonly used are unavailable. The present study characterized the PKs and PK‐PD relationship of 15, 25, and 30 mg of orally administered psilocybin in 28, 23, and 28 healthy subjects, respectively. Plasma levels of unconjugated psilocin (the psychoactive metabolite of psilocybin) and corresponding subjective effects were repeatedly assessed up to 24 hours. PK parameters were determined using compartmental modeling. Concentration‐subjective effect relationships were described using PK‐PD modeling. Mean (95% confidence interval) maximal psilocin concentrations were 11 ng/mL (10‐13), 17 …
学术搜索中的文章
F Holze, AM Becker, KE Kolaczynska, U Duthaler… - Clinical Pharmacology & Therapeutics, 2023